Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding

Phase 1 Withdrawn University of Saskatchewan

RandomizedParallel-groupDouble-blindTreatment

Summary

This study compares two treatments for the management of heavy menstrual bleeding, ulipristal acetate (UPA) and tranexamic acid (TEA), on health-related quality of life. Half of the participants will receive UPA and a placebo, and the other half will receive TEA and a placebo.

Timeline

Start: 2020-01
Primary completion: 2020-01
Completion: 2020-01-17

Outcome

Outcome not reported

Stopped: “PI made the decision to not continue the study. It was at the Health Canada review stage.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	TEA	Unknown	500 mg	—
Subject	UPA	Unknown	5 mg	—

Indications

No indication recorded.